Exelixis Stock News

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value inve

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value o

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Regeneron boasts a pair of growth drivers that should still have plenty of fuel left. Exelixis is close to expanding its lineup with a promising late-stage candidate.

Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. T

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investo

Exelixis Inc. (EXEL, Financial) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to treat patients with various types of cancer.

Exelixis is an innovative, oncology-focused drugmaker with some exciting programs in the works. Adyen's solid position in the fintech industry should allow it to escape from its recent slump.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,

The heavy selling pressure might have exhausted for Exelixis (EXEL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i

Exelixis (EXEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.

Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for t